GRI Bio, Inc.【GRI】
時価総額
$22.9万
PER
免疫応答異常に伴う炎症・線維化疾患向け治療の新興企業。NKT細胞標的の主力候補GRI-0621を開発。2022年12月の主要投資家による1万2250ドル出資、2023年4月の合併を実施。米国ラホヤ拠点で臨床開発を展開。
| 2021年 12月31日 | 2022年 12月31日 | 2023年 12月31日 | 2024年 12月31日 | |
| Cash and cash equivalents | 4 | 4 | 2 | 5 |
| Prepaid expenses and other current assets | 1 | 0 | 1 | 1 |
| Total current assets | 8 | 4 | 3 | 6 |
| Property and equipment, net | - | - | 0 | 0 |
| Operating lease right-of-use assets | - | - | 0 | 0 |
| Total assets | 8 | 4 | 3 | 6 |
| Accounts payable | 1 | 1 | 1 | 1 |
| Accrued expenses | 1 | 1 | 1 | 1 |
| Operating Lease, Liability, Current | - | - | 0 | 0 |
| Total current liabilities | 2 | 2 | 3 | 2 |
| Operating Lease, Liability, Noncurrent | - | - | - | 0 |
| Total liabilities | 3 | 2 | 3 | 2 |
| Common Stock, Value, Outstanding | - | 0 | - | - |
| Additional paid-in-capital | 28 | 31 | 32 | 44 |
| Accumulated deficit | -22 | -29 | -32 | -40 |
| Total stockholders' equity | 6 | 2 | 0 | 4 |
| Total liabilities and stockholders' equity | 8 | 4 | 3 | 6 |